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There is strong evidence that the insulin-like growth factor (IGF)
system (namely IGFs, IGF receptors, IGF binding proteins) is repre-
sented in the central nervous system (CNS) and plays an important
neuroprotective role by favouring neuronal development, metabo-
lism, survival and regeneration (1–4). Similarly, experimental evi-
dence strongly supports a neurotrophic and neuroprotective role of
oestrogens both in vitro and in vivo (5–7). Furthermore, a strong
link between oestrogen receptors (ERs) and the IGF-1 receptor (IGF-
1R) occurs in the brain (8). Many neurons and astrocytes express
both receptors and 17b-oestradiol is able to activate IGF-1R and its
signalling pathways, leading to the activation of Akt that, in turn,
regulates synaptic plasticity (9) and favours neuronal survival
(10,11). On the other hand, IGF-1 can regulate the transcriptional
activity of ERs. Indeed, IGF-1 may activate ERs in the absence of
oestrogens (12,13), inducing ER-mediated gene expression in differ-
ent cell types including neuronal cells (14–16).
We have previously demonstrated that, in human foetal neuro-
blast long-term cell cultures (FNC cells), the neuroprotective effects
of oestrogens are, at least in part, mediated by seladin-1 (SELective
AD INdicator-1) (17,18). This protein, which has been found to be
down-regulated in brain regions affected by Alzheimer’s disease
(AD) (19), confers resistance against ß-amyloid-mediated toxicity
and oxidative stress by acting as an anti-apoptotic factor via the
inhibition of caspase-3 activation (19). Furthermore, it was subse-
quently demonstrated that the seladin-1 gene corresponds to the
gene encoding 3ß-hydroxysterol D24-reductase (DHCR24), which
catalyses the reduction of the D24 double bond of desmosterol to
produce cholesterol (20). There is evidence that the amount of cell
cholesterol may be a critical factor for CNS homeostasis. One of
the mechanisms of b-amyloid toxicity is the generation of mem-
brane pores permeable to toxic calcium ions. This mechanism is
enhanced in cholesterol-depleted membranes, whereas it is mark-
edly reduced in cholesterol-enriched membranes (21,22). Accord-
ingly, reduced membrane lipids in the cortex of AD transgenic mice
have been detected (23). Furthermore, the amount of cell choles-
terol may also affect amyloidogenesis. Indeed, a moderate decrease
in cholesterol levels, similar to that occurring in the nerve cells
membrane of AD patients, has been shown to increase b-amyloid
production (24–26).
In a previous study, we have demonstrated that FNC cells express
IGF-1R and IGF-1. These cells also secrete IGF-1 and its release is
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Insulin-like growth factor-1 (IGF-1) and oestrogens interact with each other as neuroprotective
factors. We have previously demonstrated that 17b-oestradiol protects against b-amyloid and
oxidative stress toxicity and increases the amount of cell cholesterol in human foetal neuro-
blasts (FNC). The present study aimed: (i) to assess the protective effects of IGF-1 in FNC cells;
(ii) to investigate the relationship between IGF-1 and 17b-oestradiol; and (iii) to determine
whether cholesterol was a major mediator of the effects of IGF-1, similarly to 17b-oestradiol.
We found that IGF-1 effectively exerts neuroprotective effects in FNC cells. We also demon-
strated that the IGF-1 receptor (IGF-1R) pathway is needed to maintain oestrogen-mediated
neuroprotection. Finally, we found that, opposite to 17b-oestradiol, IGF-1 did not cause a signif-
icant increase in cell cholesterol. These findings indicate that a cross-talk between IGF-1 and
17b-oestradiol occurs in FNC cells. In particular, the activation of the IGF-1R cascade appears to
be fundamental to warrant 17b-oestradiol-mediated neuroprotection, even though cell choles-
terol does not play a major role as an effector of this pathway.
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cell growth and significantly increases the expression level of sela-
din-1 (27). The present study aimed: (i) to investigate on the neuro-
protective effects of IGF-1 in FNC cells; (ii) to determine whether
these effects are, at least in part, related to the amount of cell cho-
lesterol; and (iii) to identify the presence of a cross-talk between
IGF-1 and 17b-oestradiol in this cell model.
Materials and methods
Cell cultures
The primary neuroblast long term cell culture FNC was established, cloned
and propagated in vitro from human foetal olfactory neuroepithelium (28).
FNC cells synthesise both neuronal proteins and olfactory markers and
respond to odorant stimuli, suggesting their origin from the stem cell com-
partment that generates mature olfactory receptor neurons (29). In addition,
they display neuroendocrine features (30). FNC cell cultures were propagated
at 37 C in 5% CO2 in Coon’s modified Ham’s F-12 medium (Sigma, St
Louis, MO, USA), 10% foetal bovine serum (FBS) (HyClone, Logan, UT, USA)
and antibiotic solution (penicillin 100 IU ⁄ml; streptomycin 100 lg ⁄ml) (PAA,
Colbe, Germany). The B4 clone, showing the highest levels of expression of
neuronal and olfactory markers (28), was used in the present study.
Viability assays
Cell viability after b-amyloid exposure was determined by [3-(4,5-dim-
ethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazo-
lium] (MTS; Promega, Milan, Italy) assay, as described previously (18). Briefly,
cells were seeded in 96-well plates for 24 h in growth medium. Recom-
mended instructions for b-amyloid (Calbiochem, Darmstadt, Germany)
preparation were observed: the lyophilised peptide was solubilised in 50 mM
Tris-HCl (pH 9.0) and then diluted to the appropriate concentration with
calcium- and magnesium-free PBS. Successively, the peptide was incubated
at 37 C for 48 h to allow aggregation. Thereafter, the cells were exposed
to 10 nM IGF-1 or 10 nM 17b-oestradiol (Sigma) in the presence or in the
absence of 1 lM of the ER antagonist ICI 182 780 (Sigma) or 1 lg ⁄ml of
the IGF-1R antagonist JB-1 (Sigma) for 48 h. During the last 20 h of incu-
bation, cells were treated with 1 lM b-amyloid or 100 lM H2O2. Multiwell
dishes were analysed using an enzyme-linked immunosorbent assay plate
reader (Seac-Radim, Moncalieri, Italy) and optical density (OD) at 490 nm
was considered directly proportional to the number of living cells. Each
experimental point was performed in six replicates and the results were
expressed as the OD ⁄well (mean  SE of three different experiments).
To assess the resistance against H2O2-mediated oxidative stress, viable
cells were also determined by Trypan blue dye exclusion test, as described
previously (18). Briefly, the cells were cultured in 25-cm2 flasks in growth
medium in the presence or in the absence of 10 nM IGF-1 for 48 h. Cells
were then treated with 100 lM H2O2 during the last 20 h of incubation.
Subsequently, cells were stained with Trypan blue dye for 1 min. Blue-posi-
tive and white-negative cells were counted in ten · 20 fields and the results
were expressed as mean  SE percentage of dead ⁄ total cells in three differ-
ent experiments.
Cell proliferation
FNC cell growth was evaluated by the 3H-thymidine incorporation assay.
Cells were cultured in 24-well plates at 5 · 104 cells ⁄well for 48 h, in the
presence of 10 nM IGF-1. During the last 20 h of incubation, cells were trea-
ted with 100 lM H2O2 and pulsed with 1 lCi
3H-thymidine. Cells were then
harvested and samples were analysed using a b-counter. Each experimental
point was performed in six replicates and results were expressed as counts
per minute ⁄well (mean  SE of three different experiments).
Cell cholesterol measurement
The amount of cell cholesterol in control FNC cells and in cells treated with
10 nM IGF-1 (in the presence or in the absence of 1 lM ICI 182 780) or
10 nM 17b-oestradiol (in the presence or in the absence of 1 lg ⁄ml JB-1)
for 48 h was determined by gas chromatography-mass spectrometry
(GC-MS) as described previously (22), with minor modifications. Briefly, cells
were maintained in medium without FBS for 6 h, then lysed in 1 N NaOH
and the cell lysate was used for cholesterol quantification or frozen for
storage at )80 C until cholesterol measurement. Aliquots corresponding to
10 lg of protein, as determined by Bradford staining, were used. After the
addition of stigmasterol (1000 ng) as an internal standard, sterols were
extracted with n-hexane, derivatised with N,O-bis(trimethylsilyl)trifluoroace-
tamide at 10% in trimethyl-chlorosilane and automatically injected in a
Hewlett-Packard GC-MS system (Hewlett-Packard, Palo Alto, CA, USA). A six-
point calibration curve in the 25–1000 ng cholesterol range was used for
cholesterol quantification. The peak area ratios were calculated using the
signals at m ⁄ z 458 and 484 for cholesterol and stigmasterol, respectively.
Each point was performed in duplicate and the results represent the
mean  SE of three experiments.
Quantitative reverse transcriptase-polymerase chain
reaction (RT-PCR) analysis
Total RNA was isolated using Nucleospin RNAII (Macherey-Nagel, Duren,
Germany) with DNAse treatment in accordance with the manufacturer’s
instructions. The concentration was determined spectrophotometrically with
Nanodrop ND-1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA). The
amount of ERa, ERb and IGF-1R mRNA was determined by real-time RT-
PCR using pre-developed assays (Hs00174860_m1; HS00230957_m1 and
Hs00609566_m1 respectively; Applied Biosystems, Foster City, CA, USA).
According to the comparative Ct (threshold cycle) method, the amount of
target mRNA was normalised to the endogenous reference 18S RNA
(Hs99999901_s1) and also relative to an internal control and was calculated
by the 2)DDCt method. The results were expressed as the mean  SE mRNA
fold variations compared to the control. All measurements were carried out
in triplicate and three experiments were performed.
Statistical analysis
Statistical differences were analysed using one-way ANOVA or Student’s t-test.
When the Student’s t-test was used, significance was adjusted for multiple
comparisons of means using Bonferroni’s approximation.
Results
Effects of IGF-1 on cell viability and proliferation
The presence of the expression and secretion of IGF-1 and of the
expression of IGF-1R in FNC cells was described previously (27). In
the present study, to determine whether IFG-1 exerts neuroprotec-
tive effects in FNC cells, cells were exposed to toxic insults, such as
b-amyloid and H2O2. b-amyloid (1 lM) significantly decreased cell
viability compared to control cells, as assessed by the MTS assay
(Fig. 1A). However, in cells pre-treated with IGF-1 (10 nM), the toxic
effect of b-amyloid was effectively counteracted. Similarly, when
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the cells were exposed to H2O2 (100 lM H2O2), the number of dead
cells significantly increased, as shown by Trypan blue dye exclusion
test experiments, whereas pre-treatment with IGF-1 was able also
to significantly prevent cell death (Fig. 1B).
With regard to cell proliferation, we observed a significant reduc-
tion, upon exposure to H2O2, as assessed by
3H-thymidine incorpo-
ration (77.5  7% reduction versus control cells; mean  SE). This
inhibitory effect was significantly reversed in cells that were pre-
exposed to IGF-1 (Fig. 2).
Effects of IGF-1 on cell cholesterol
We had previously demonstrated that cell cholesterol is an essential
mediator of the neuroprotective effects of oestrogens, which
increase the synthesis of the neuroprotective factor seladin-1
(17,18). IGF-1 is also able to increase the expression of this factor
(30). To determine whether cell cholesterol may be a possible factor
mediating the protective effects of IGF-1 in nerve cells, we mea-
sured the amount of cholesterol in control FNC cells and in cells
treated with 10 nM IGF-1 for 48 h, by GC ⁄MS. We found that,
although in cells exposed to IGF-1 there was a trend toward an
increased amount of cholesterol, there was no significant difference
versus control cells (11.2  7.8%; mean  SE, percentage increase
versus control).
Cross-talk between IGF-1 and 17b-oestradiol in FNC cells
To determine whether a cross-talk between IGF-1 and 17b-oestra-
diol occurs in FNC cells, similar to that described in other cell mod-
els (8), we followed various experimental approaches. First, we
investigated whether IGF-1 affects the expression levels of ERs
and ⁄ or 17b-oestradiol affects the expression of IGF-1R. Accord-
ingly, we treated the cells with IGF-1 (10 nM) or with 17b-oestra-
diol (10 nM) for 48 h. Significantly higher levels of ERa mRNA, but
not of ERb, were detected in cells exposed to IGF-1 compared to
untreated cells (Fig. 3). Conversely, treatment with 17b-oestradiol
did not affect the amount of IGF-1R mRNA.
Subsequently, we determined whether and how oestrogen and
IGF-1 signalling cascades interact with each other by using the ER
antagonist ICI 182 780 and the IGF-1R antagonist JB-1. The two
antagonists did not show any effect per se on cell viability (Fig. 4).
In a first set of experiments, we determined whether the two
antagonists effectively counteracted the protective effects of the
corresponding agonists against H2O2-induced toxicity. We con-
firmed that both 17b-oestradiol (10 nM) and IGF-1 (10 nM) were
able to prevent oxidative stress toxicity, although we demonstrated
that the protective effect was lost in the presence of ICI 182 780
(1 lM) and JB-1 (1 lg ⁄ml), respectively (Fig. 4). Next, we investi-
gated whether the protective effects of IGF-1 were maintained in
the presence of the ER antagonist and, simultaneously, whether
17b-oestradiol-mediated protection was maintained in the presence


















Fig. 2. Role of insulin-like growth factor-1 (IGF-1) (10 nM, 48 h) against
the inhibitory effect of H2O2 (100 lM, 20 h) on cell proliferation. cpm
(counts per minute) ⁄well, as measured by a b-counter. *P < 0.05 versus
control cells, cells treated with IGF-1 or IGF-1 + H2O2. n = 3, six repli-
cates ⁄ experiment.

















































Fig. 1. (A) Effect of insulin-like growth factor-1 (IGF-1) (10 nM, 48 h)
against b-amyloid (BA) (1 lM, 20 h)-induced toxicity in human foetal neuro-
blasts (FNC). *P < 0.05 versus control cells, cells treated with IGF-1 or with
IGF-1 + BA. OD ⁄well = optical density (absorbance at 490 nm) ⁄well; n = 3,
six replicates ⁄ experiment. (B) Effect of IGF-1 (10 nM, 48 h) against H2O2
(100 lM, 20 h)-induced toxicity. *P < 0.05 versus control cells, cells treated
with IGF-1 or IGF-1 + H2O2. n = 3, cells were counted in ten 20· fields.
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of the IGF-1R antagonist. We found that the exposure of FNC cells
to IGF-1 and ICI 182 780 or to 17b-oestradiol and JB-1 did not
affect per se cell viability. IGF-1 readily counteracted the toxic
effect of H2O2 in the presence of ICI 182 780, thus indicating that
the ER signalling pathway is not necessary to warrant the protec-
tive effects of IGF-1. Conversely, the protective effect of 17b-oes-
tradiol against oxidative stress toxicity was lost in the presence of
the IGF-1R antagonist JB-1, thus suggesting that the IGF-1R sig-
nalling cascade is involved in oestrogen-mediated neuroprotection
in FNC cells (Fig. 5).
To determine whether the loss of the protective effect of 17b-
oestradiol in the presence of JB-1 and, conversely, the maintenance
of the protective effect of IGF-1 in the presence of ICI 182 780
might be a result, at least in part, of a different amount of cell
cholesterol, we measured cholesterol in cells subjected to different
treatments. As previously demonstrated (17), we found a significant
increase of cholesterol amount in cells exposed to 17b-oestradiol
(Fig. 6). In cells treated with 17b-oestradiol + JB-1, the level of cell
Con
































Fig. 5. Cell viability experiments, showing that the protective effects of
insulin-like growth factor-1 (IGF-1) (10 nM, 48 h) against H2O2 (100 lM,
20 h)-induced toxicity are maintained in the presence of ICI 182 780 (ICI)
(1 lM, 48 h), whereas the protective effects of 17b-oestradiol (E2) (10 nM,
48 h) are lost in the presence of JB-1 (1 lg ⁄ml, 48 h). *P < 0.05 versus



























Fig. 3. Effect of insulin-like growth factor-1 (IGF-1) (10 nM, 48 h) on the
expression of oestrogen receptor (ER)a and ERb and of 17b-oestradiol (E2)
(10 nM, 48 h) on IGF-1 receptor (IGF-1R), as assessed by quantitative reverse
transcriptase-polymerase chain reaction. *P < 0.05 versus control. n = 3,














































Fig. 4. Cell viability experiments, showing that the protective effects of
17b-oestradiol (E2) (10 nM, 48 h) and insulin-like growth factor-1 (IGF-1)
(10 nM, 48 h) against H2O2 (100 lM, 20 h)-induced toxicity are lost in the
presence of the corresponding antagonists, ICI 182 780 (ICI) (1 lM, 48 h)
and JB-1 (1 lg ⁄ml, 48 h). *P < 0.05 versus control cells. n = 3, six repli-
cates ⁄ experiment.



























Fig. 6 Cell cholesterol amount (measured by gas chromatography-mass
spectrometry) in control cells, cells treated with 17b-oestradiol (E2) (10 nM,
48 h), insulin-like growth factor-1 (IGF-1) (10 nM, 48 h), E2 + JB-1 (1 lg ⁄ml,
48 h) and IGF-1 + ICI 182 780 (ICI) (1 lM, 48 h). *P < 0.05 versus control
cells. n = 3, two replicates ⁄ experiment.
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cholesterol was not significantly different from the level measured
in cells treated with 17b-oestradiol alone. This result, together with
the finding that JB-1 prevented the neuroprotective effect of
17b-oestradiol, suggests that cholesterol per se is not sufficient to
confer oestrogen-mediated neuroprotection. Furthermore, the
amount of cholesterol in cells treated with IGF-1 or with IGF-
1 + ICI 182 780 did not differ from the amount detected in control
FNC cells. These data further support an important role for cell
cholesterol in affecting ER-mediated, but not IGF-1R-mediated,
neuroprotection in FNC cells.
Discussion
IGF-1 is known to play an important neuroprotective role by
favouring neuronal proliferation and survival (8). Accordingly, there
is evidence that the IGF system may be altered in AD, the most
common neurodegenerative disease in the elderly. IGF-1 gene poly-
morphisms have been associated with a greater risk for the onset
of the disease through their effects on IGF-1 levels (31). Indeed, it
has been demonstrated that lower levels of intracerebral IGF-1 in
AD patients, together with the development of IGF-1 resistance,
determine b-amyloid accumulation as a consequence of a reduced
clearance (32–34). Furthermore, IGF-1 has also been associated with
the preferential activation of the non-amyloidogenic a-secretase
processing of amyloid precursor protein (35).
In the present study, we first demonstrated that IGF-1 exerts
protective effects in FNC. These cell cultures were established,
cloned and propagated several years ago, starting from GnRH-
secreting cells isolated from human foetal olfactory epithelium.
FNC cells show unique features because they synthesise both neu-
ronal proteins and olfactory markers and respond to odorant stim-
uli, suggesting their origin from the stem cell compartment that
generates mature olfactory receptor neurons (28,29). These human
neuronal precursors represent a more appropriate in vitro model
for targeting studies related to neurodegenerative diseases com-
pared to animal cell or tumoural cell lines models, which are usu-
ally employed. We have previously shown that FNC cells are a
suitable cell model to study the role of IGF-1 in neuroprotection.
Indeed, these cells express both IGF-1 and IGF-1R and release IGF-
1 in the culture medium (27). In the present study, we observed
that IGF-1 is able to prevent b-amyloid- and H2O2-induced cell
toxicity, as assessed by cell viability assays. Furthermore, we dem-
onstrated that IGF-1 effectively counteracts the inhibitory effect of
H2O2 on cell proliferation.
To determine whether the protective effects of IGF-1 in FNC cells
might be related to an optimal amount of cell cholesterol, as sug-
gested by our previous finding that IGF-1 increases the expression
of the seladin-1 gene (27), we measured cholesterol levels in con-
trol FNC cells and in cells exposed to IGF-1. We found that cell
cholesterol was not significantly increased by IGF-1. This finding
suggests that, in contrast to our previous experimental data show-
ing that cell cholesterol is an essential mediator of the neuropro-
tective effects of oestrogens in FNC cells (17), IGF-1-mediated
neuroprotection does not appear to involve cholesterol as a major
factor, at least in this cell model.
Despite the different role of intracellular cholesterol, our present
and previous findings indicate that both oestrogens and IGF-1 exert
neuroprotective effects in FNC cells, thus suggesting the presence
of a cross-talk between these hormones. Some studies addressed
this issue by using specific receptor antagonists. One study clearly
showed that rat hippocampal cell death induced by in vivo kainic
acid administration was prevented by either 17b-oestradiol or IGF-
1. However, none of these hormones was able to prevent cell death
also when animals were treated with the IGF-1R antagonist JB-1 or
with the ER antagonist ICI 182 780, respectively (36). Other studies
showed that ICI 182 780 or JB-1 blocked the induction of neuro-
genesis or neurite outgrowth induced by IGF-1 or 17b-oestradiol,
respectively, both in vitro and in vivo (37,38). In an in vivo model
of global ischaemia-induced neuronal cell death in rats, JB-1 abol-
ished the pro-survival effects of 17b-oestradiol (39). To assess the
presence of a cross-talk between oestrogens and IGF-1 in our
human neuronal cell model, we also performed additional cell via-
bility experiments after oxidative stress, using different combina-
tions of 17b-oestradiol, IGF-1, ICI 182 780 and JB-1. Our results
indicated that the IGF-1R signalling cascade is involved in the neu-
roprotective effects of oestrogens, although the ER signalling path-
way is not necessary for IGF-1-mediated neuroprotection in FNC
cells. This suggests that the activation of one or more factors that
are associated to the IGF-1R pathway is sufficient to exert neuro-
protection.
Furthermore, to determine whether variations in cell cholesterol
amount might be, at least partially, responsible for the loss of the
protective effect of 17b-oestradiol in the presence of JB-1, as well
as the maintenance of the protective effect of IGF-1 in the pres-
ence of ICI 182 780, we measured cholesterol levels in cells sub-
jected to different treatments. We found that JB-1 did not blunt
the stimulatory effect of 17b-oestradiol on cell cholesterol (17),
whereas IGF-1 or IGF-1 + ICI 182 780 did not cause any change
compared to control cells. Overall, these findings support a pivotal
role of the IGF-1R pathway in mediating the neuroprotective
effects of oestrogens. However, unlike the ER pathway, cell choles-
terol does not appear to play a major role in mediating the neuro-
protective effects elicited by the activation of the IGF-1R cascade,
which are likely the result of other mechanisms, such as the IGF-1-
induced anti-apoptotic effects (1–3). Therefore, although an optimal
amount of cell cholesterol appears to be essential, as previously
reported (17), this is not sufficient to warrant the neuroprotective
effects of oestrogens, which appear to involve the activation of
multiple pathways.
Finally, in the present study, we demonstrated that IGF-1 up-reg-
ulates the expression of ERa, yet not of ERb, whereas 17b-oestradiol
does not affect the expression of IGF-1R. These data, together with
our previous observation that 17b-oestradiol stimulates the release
of IGF-1 in FNC cells (30), lead us to hypothesise a model in which:
(i) 17b-oestradiol and IGF-1 mutually interact in protecting nerve
cells and (ii) a reinforcement mechanism is provided by the presence
of an autocrine loop in which ERa activation stimulates the release
of IGF-1, which in turn induces the expression of ERa.
Overall, the data reported in the present study appear to support
the hypothesis that the interaction between IGF-1 and oestrogens
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in neuroprotection may be relevant also in defining possible
strategies against neurodegenerative diseases, and primarily against
AD. With regard to this issue, although clinical trials for the
prevention ⁄ treatment of AD with oestrogens have been performed
(40,41), no trial so far has addressed the use of IGF-1. However,
the hypothetical use of this growth factor in the treatment of CNS
pathologies, including AD, has been proposed several times in the
last 20 years (42,43). It is known that the cholinesterase-inhibitor
donezepil increases plasma levels of GH and IGF-1 in AD patients
(44) and that the lack of a response to this drug is associated with
lower levels of IGF-1 (45). Accordingly, an enhancement in spatial
learning and memory after peripheral administration of GH in rats
displaying AD-like deficiences has been recently reported and it is
very likely to be a result of the increased release of IGF-1 (46). A
phase II trial, aiming at evaluating the effects of GHRH in healthy
older men and women and in those with mild cognitive impair-
ment, is currently recruiting participants (http://www.clinicaltrials.
gov, trial no. NCT00257712). These interventional studies, together
with the basic science, are expected to provide further information
and to enhance our knowledge about the neuroprotective effects of
IGF-1 and its possible role against neurodegenerative diseases.
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